烟酰胺与丙酮酸用于开角型青光眼神经增强:一项2期随机临床试验
该2期随机双盲安慰剂对照试验在单家学术机构纳入42例已治疗的开角型青光眼且至少1眼中度视野缺损患者,按2:1随机接受口服烟酰胺(1000至3000 mg)联合丙酮酸(1500至3000 mg)递增剂量或安慰剂,32例完成研究。结果显示治疗组视野改善测试点数量显著高于安慰剂组,模式标准差变化率提示改善,但平均偏差和视野指数变化率无显著差异,无严重不良事件。
要点
- 治疗组视野改善测试点中位数15个,安慰剂组7个,差异显著(P=0.005)。
- 模式标准差变化率治疗组-0.06 dB/周 vs 安慰剂组0.02 dB/周,提示改善(P=0.02)。
- 平均偏差和视野指数变化率两组无显著差异,研究期间无严重不良事件。
核心结论
- 烟酰胺与丙酮酸联合治疗在短期内显著改善开角型青光眼患者视野功能,支持既往实验研究提示这些药物在青光眼神经保护中的可能作用,并确认需要长期研究以确定其减缓进展的效用。
研究设计与样本
- 2期随机双盲安慰剂对照临床试验,在单家学术机构进行,评估197例患者,纳入42例已治疗的开角型青光眼且至少1眼中度视野缺损患者,按2:1随机分配,32例完成研究并纳入最终分析。
- 参与者平均(SD)年龄64.6(9.8)岁,21例(66%)为女性,招募于2019年4月进行,患者监测至2020年12月,数据分析于2021年1月至5月进行。
主要发现
- 干预组29例中22例(76%)和安慰剂组13例中12例(92%)接受了分配,32例参与者(32眼;比例21:11)完成研究(干预组21例,安慰剂组11例)。
- 中位(IQR)随访时间为2.2(2.0-2.4)个月,研究期间未报告严重不良事件。
- 治疗组视野改善测试点数量显著高于安慰剂组(中位数[IQR],15[6-25] vs 7[6-11];P=0.005)。
- 模式标准差变化率提示治疗组较安慰剂组改善(中位数,-0.06 vs 0.02 dB/周;95%CI,0.02至0.24;P=0.02),但平均偏差(0.04 vs -0.002 dB/周;95%CI,-0.27至0.09;P=0.35)和视野指数(0.09 vs -0.02%/周;95%CI,-0.53至0.36;P=0.71)变化率无显著差异。
关键数值与推荐
- 主要终点为研究眼视野测试中改善超过正常变异性的测试点数量。
- 次要终点为视野全局指数(平均偏差、模式标准差和视野指数)的变化率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要长期研究以确定这些药物减缓青光眼进展的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Open-angle glaucoma may continue to progress despite significant lowering of intraocular pressure (IOP). Preclinical research has suggested that enhancing mitochondrial function and energy production may enhance retinal ganglion cell survival in animal models of glaucoma, but there is scant information on its effectiveness in a clinical setting. OBJECTIVE: To test the hypothesis that a combination of nicotinamide and pyruvate can improve retinal ganglion cell function in human glaucoma as measured with standard automated perimetry. DESIGN, SETTING, AND PARTICIPANTS: In this phase 2, randomized, double-blind, placebo-controlled clinical trial at a single academic institution, 197 patients were assessed for eligibility. Of these, 42 patients with treated open-angle glaucoma and moderate visual field loss in at least 1 eye were selected for inclusion and randomized. A total of 32 completed the study and were included in the final analysis. The mean (SD) age was 64.6 (9.8) years. Twenty-one participants (66%) were female. Participant race and ethnicity data were collected via self-report to ensure the distribution reflected that observed in clinical practice in the US but are not reported here to protect patient privacy. Recruitment took place in April 2019 and patients were monitored through December 2020. Data were analyzed from January to May 2021. INTERVENTIONS: Ascending oral doses of nicotinamide (1000 to 3000 mg) and pyruvate (1500 to 3000 mg) vs placebo (2:1 randomization). MAIN OUTCOMES AND MEASURES: Number of visual field test locations improving beyond normal variability in the study eye. Secondary end points were the rates of change of visual field global indices (mean deviation [MD], pattern standard deviation [PSD], and visual field index [VFI]). RESULTS: Twenty-two of 29 participants (76%) randomized to the intervention group and 12 of 13 participants (92%) randomized to placebo received their allocation, and 32 participants (32 eyes; ratio 21:11) completed the study (21 from the intervention group and 11 from the placebo group). Median (IQR) follow-up time was 2.2 (2.0-2.4) months. No serious adverse events were reported during the study. The number of improving test locations was significantly higher in the treatment group than in the placebo group (median [IQR], 15 [6-25] vs 7 [6-11]; P = .005). Rates of change of PSD suggested improvement with treatment compared with placebo (median, -0.06 vs 0.02 dB per week; 95% CI, 0.02 to 0.24; P = .02) but not MD (0.04 vs -0.002 dB per week; 95% CI, -0.27 to 0.09; P = .35) or VFI (0.09 vs -0.02% per week; 95% CI, -0.53 to 0.36; P = .71). CONCLUSIONS AND RELEVANCE: A combination of nicotinamide and pyruvate yielded significant short-term improvement in visual function, supporting prior experimental research suggesting a role for these agents in neuroprotection for individuals with glaucoma and confirming the need for long-term studies to establish their usefulness in slowing progression. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03797469.
引用
- De Moraes CG, John SWM, Williams PA, et al. Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2022. PMID: 34792559. doi:10.1001/jamaophthalmol.2021.4576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。